丹红注射液联合依达拉奉治疗急性脑梗死的疗效和安全性系统评价

发布时间：2018-05-08 10:03

本文选题：丹红注射液 + 依达拉奉　；参考：《中华中医药杂志》2017年10期

【摘要】：目的:系统评价丹红注射液联合依达拉奉治疗急性脑梗死的疗效和安全性。方法:通过检索中国生物医学文献数据库、相关期刊论文、维普期刊数据库、万方期刊数据库、美国国立医学图书馆数据库从2011年1月至2016年12月的中英文文献,选择符合纳入及排除标准的随机对照试验,对纳入文献进行质量评价,采用Rev Man 5.3版软件进行Meta分析。结果:共纳入24个研究,2 266例患者。丹红注射液联合依达拉奉在疗效方面对比单用丹红注射液、依达拉奉及常规治疗有优势,疗效合并效应量(RR=1.22,95%CI[1.18,1.27],P0.00001);在神经功能缺损改善方面优于丹红对照组,合并效应量(M D=-3.58,95%CI[-4.23,-2.93],P0.00001);在日常生活能力改善方面比丹红注射液对照组及依达拉奉对照组有效,合并效应量(MD=15.62,95%CI[13.43,17.81],P0.00001);而在安全性方面与对照组无差异,合并效应量(RR=1.46,95%CI[0.61,3.47],P=0.91)。结论:丹红注射液联合依达拉奉治疗急性脑梗死疗效较单用一种注射剂及常规治疗显著,能减轻近期致残率,且较安全,但仍需后续大样本、高质量文献支持研究。
[Abstract]:Objective: to evaluate the efficacy and safety of Danhong injection combined with Edaravone in the treatment of acute cerebral infarction. Methods: Chinese Biomedical Literature Database, Chinese Journal Full-text Database, Weip Journal Database, Wanfang Journal Database, and National Library of Medicine database were searched from January 2011 to December 2016. A randomized controlled trial according to the inclusion and exclusion criteria was selected to evaluate the quality of the inclusion literature, and Meta analysis was carried out with Rev Man 5.3 software. Results: a total of 2 266 patients were enrolled in 24 studies. Danhong injection combined with Edaravone was superior to Danhong injection, Edaravone and conventional therapy in curative effect combined with RRX 1.22995 CI [1.181.27] P0.00001, and was superior to Danhong group in improving neurological function defect. The combined effect was better than that of danghong injection group and Edaravone control group (P 0.00001), but there was no difference in safety between the two groups (P 0.00001), but there was no difference between the two groups in safety, and the combined effect was higher than that in the control group (RRN 1.4695 CI [0.61C 3.47] / P 0.91C), and the combined effect was higher than that in the control group (P 0.00001), but there was no difference between the two groups in the safety of the combined effect (P 0.00001), and the combined effect was higher than that in the danghong injection group and the Edaravone control group (P 0.00001), but there was no difference between the two groups in terms of safety. Conclusion: Danhong injection combined with Edaravone in the treatment of acute cerebral infarction is more effective than single injection and routine treatment, can reduce the short-term disability rate, and safer, but still need to follow up large sample, high quality literature to support the study.
【作者单位】：湖南中医药大学第一附属医院;湖南中医药大学;
【基金】：湖南省科技厅重点项目(No.2014SK2007)~~
【分类号】：R743.3

【相似文献】